TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38588687

Group type: EXPERIMENTAL
Intervention: 10-h per-day time-restricted eating (TRE) for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10-h per-day time-restricted eating (TRE) for 3 months (per-protocol analysis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 38588696

Group type: EXPERIMENTAL
Intervention: Neoadjuvant olaparib with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38588914

Group type: EXPERIMENTAL
Intervention: Early-onset preeclampsia (N=139)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Late-onset preeclampsia
Number of subjects: 911
Study: 38588926

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: MAD vs CPAP
Number of subjects: 220
Study: 38588927

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1910
Study: 38588928

Group type: EXPERIMENTAL
Intervention: Telemedicine-based approach
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 337
Study: 38588929

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg daily)
Number of subjects: 6522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study: 38589266

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: IVP: yes
Number of subjects: 197

Group type: COMPARATOR
Intervention: IVP: no
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: IVPs (overall)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: IVPs (separate analyses for each trial arm)
Number of subjects: 197
Study: 38589451

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Vitamin D testing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Screening for low BMD by DXA and vitamin D supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 51
Study: 38589574

Group type: EXPERIMENTAL
Intervention: Concurrent inhibition of oncogenic and wild-type RAS-GTP
Number of subjects: 0
Study: 38589582

Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic, strength, and stretching exercises) for 60 min, three times a week, during six months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: No exercise (control group).
Number of subjects: 30
Study: 38589630

Group type: EXPERIMENTAL
Intervention: Capsaicin stimulation of the tongue (STC)
Number of subjects: 16
Study: 38589780

Group type: EXPERIMENTAL
Intervention: Patient prioritization software
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Standard dashboard (control)
Number of subjects: 1599
Study: 38589856

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine, cisplatin, and nabpaclitaxel (GAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with GAP
Number of subjects: 0
Study: 38589860

Group type: EXPERIMENTAL
Intervention: 2-fraction SABR (27 Gy in 2 fractions)
Number of subjects: 502

Group type: COMPARATOR
Intervention: 5-fraction SABR (40 Gy in 5 fractions)
Number of subjects: 502
Study: 38589875

Group type: EXPERIMENTAL
Intervention: rPMS + iTBS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham rPMS + iTBS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 38589926

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX), 2-4 cycles before surgery and 4-6 cycles after surgery.
Number of subjects: 756

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX), 8 cycles after upfront surgery.
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX).
Number of subjects: 756

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX).
Number of subjects: 756
Study: 38589966

Group type: EXPERIMENTAL
Intervention: Diabetes self-management coaching program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 38590093

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention
Number of subjects: 32
Study: 38590283

Group type: EXPERIMENTAL
Intervention: Endovascular treatment using the heparin-bonded Viabahn endoprosthesis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical femoropopliteal bypass
Number of subjects: 100
Study: 38590326

Group type: EXPERIMENTAL
Intervention: Prevalent cardiovascular disease (CVD)
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Angina
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Myocardial infarction
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Transient ischemic attack
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 3003
Study: 38590716

Group type: EXPERIMENTAL
Intervention: Consolidation chemoradiation (CTRT) with concurrent capecitabine at 1250 mg/m2
Number of subjects: 135

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Consolidation chemoradiation (CTRT)
Number of subjects: 135
Study: 38590831

Group type: EXPERIMENTAL
Intervention: 15g of specific collagen peptides (SCP) daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 55
Study: 38590997

Group type: EXPERIMENTAL
Intervention: Hybrid Atrial Fibrillation Convergent (HC)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Hybrid Atrial Fibrillation Convergent (HC) in LSPAF patients
Number of subjects: 153

Group type: COMPARATOR
Intervention: Endocardial catheter ablation (CA)
Number of subjects: 153
Study: 38591096

Group type: EXPERIMENTAL
Intervention: DaVinci RARP (DV-RARP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hugo RAS (H-RARP)
Number of subjects: 100
Study: 38591260

Group type: EXPERIMENTAL
Intervention: Mavacamten, 5 mg once daily with individualized dose titration at week 6
Number of subjects: 13
Study: 38591535

Group type: EXPERIMENTAL
Intervention: Vienna transcatheter aortic valve system
Number of subjects: 10
Study: 38591600

Group type: EXPERIMENTAL
Intervention: Unrestricted diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: 3-day low-residue diet
Number of subjects: 102
Study: 38591748

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase within 4.5 hours of symptom onset
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 422
Study: 38591808

Group type: EXPERIMENTAL
Intervention: Tooth extraction (TE)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Need for osteotomy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Radiation dose at the extraction site
Number of subjects: 156
Study: 38591811

Group type: COMPARATOR
Intervention: Mibavademab (0.3, 1.0, 3.0, 10, and 30 mg/kg i.v. or 300 and 600 mg subcutaneous)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Mibavademab (15 mg/kg i.v. loading dose and 10 mg/kg i.v. at weeks 3, 6, and 9)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 38591829

Group type: EXPERIMENTAL
Intervention: iFightDepression-SURVIVE (iFD-S) with treatment as usual (TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 38591949

Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 0
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 3
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 7
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV) for all three time points
Number of subjects: 279
Study: 38591997

Group type: EXPERIMENTAL
Intervention: Combination of coronary artery calcium score (Ca-score) and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Ca-score and hs-cTnT
Number of subjects: 1715

Group type: EXPERIMENTAL
Intervention: Composite of cardiovascular death and non-fatal acute myocardial infarction (AMI)
Number of subjects: 1715
Study: 38592002

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 1350
Study: 38592485

Group type: EXPERIMENTAL
Intervention: Automated oxygen control (AOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual oxygen control
Number of subjects: 0
Study: 38592605

Group type: EXPERIMENTAL
Intervention: Rapid cycling bipolar disorder (RCBD)
Number of subjects: 520
Study: 38592721

Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (including cetuximab plus avelumab, trifluridine-tipiracil plus panitumumab, irinotecan plus cetuximab, or panitumumab monotherapy)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (in patients without liver metastasis)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (in patients with liver metastasis)
Number of subjects: 114
Study: 38592753

Group type: EXPERIMENTAL
Intervention: NUTRES mHealth intervention (SMS text messages)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 494
Study: 38592771

Group type: EXPERIMENTAL
Intervention: Mindset for Depression app with 8 brief video conferencing visits with a licensed CBT therapist
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mindset for Depression app
Number of subjects: 28
Study: 38593212

Group type: EXPERIMENTAL
Intervention: 225Ac-macropa-pelgifatamab (225Ac-pelgi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 225Ac-DOTA-pelgi
Number of subjects: 0

Group type: COMPARATOR
Intervention: 225Ac-DOTA-J591
Number of subjects: 0

Group type: COMPARATOR
Intervention: 227Th-HOPO-pelgifatamab (227Th-pelgi)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 225Ac-pelgi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 225Ac-pelgi with darolutamide
Number of subjects: 0
Study: 38593221

Group type: COMPARATOR
Intervention: Leniolisib
Number of subjects: 6
Study: 38593233

Group type: EXPERIMENTAL
Intervention: Posoleucel infusion initiated within 15 to 49 days of allo-HCT, subsequently every 14 days for up to 7 doses.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Posoleucel infusion
Number of subjects: 26
Study: 38593241

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan therapy
Number of subjects: 80
Study: 38593249

Group type: EXPERIMENTAL
Intervention: Nicotinamide (1 g/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 38593348

Group type: EXPERIMENTAL
Intervention: RMC-6236 at 300 mg daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RMC-6236 at 100 mg and 300 mg daily
Number of subjects: 2
Study: 38593428

Group type: EXPERIMENTAL
Intervention: eHealth parenting intervention delivered to caregivers
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 149
Study: 38593512

Group type: EXPERIMENTAL
Intervention: Adavosertib 250 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adavosertib 200 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Number of subjects: 9
Study: 38593943

Group type: EXPERIMENTAL
Intervention: CVD education and screening (blood pressure, electrocardiogram, transthoracic echocardiogram [TTE])
Number of subjects: 498
Study: 38593947

Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg at days 0, 90, and 270) plus usual care
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 450
Study: 38594150

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Renal Replacement Therapy (RRT)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Norepinephrine/Epinephrine treatment
Number of subjects: 772

Group type: COMPARATOR
Intervention: Invasive ventilation
Number of subjects: 772

Group type: COMPARATOR
Intervention: Mechanical circulatory support
Number of subjects: 772
Study: 38594181

Group type: EXPERIMENTAL
Intervention: Any antenatal care (ANC)
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Four or more ANC visits
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: First ANC visit in the first trimester
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Distance to nearest facility
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Additional ANC visit
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: First ANC in the first trimester
Number of subjects: 8575

Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 8575
Study: 38594245

Group type: EXPERIMENTAL
Intervention: WU-04 (non-covalent inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ensitrelvir and nirmatrelvir (clinically used inhibitors)
Number of subjects: 0
Study: 38594322

Group type: EXPERIMENTAL
Intervention: Stroke-induced immunosuppression (SII)
Number of subjects: 0
Study: 38594435

Group type: EXPERIMENTAL
Intervention: Increasing adalimumab (ADA) dose intervals to 3 and then to 4 weeks.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Increasing adalimumab (ADA) dose intervals.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Prediction model based on logistic regression with relaxed LASSO.
Number of subjects: 109
Study: 38594558

Group type: EXPERIMENTAL
Intervention: Hyperpolarized [1-
Number of subjects: 6
Study: 38594603

Group type: EXPERIMENTAL
Intervention: GARD-optimized doses with simultaneous integrated boost (SIB) doses of 70 and 60 Gy in 25 fractions to the highest and intermediate radioresistant habitats, while the remaining volume receives standard 50 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mpMRI taken between weeks two and three of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mpMRI after completion of radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid biopsy with mpMRI
Number of subjects: 0
Study: 38594621

Group type: EXPERIMENTAL
Intervention: BCHE-K carriers (n=11)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BCHE-K noncarriers (n=22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: APOE4 carriers (N=33)
Number of subjects: 45

Group type: COMPARATOR
Intervention: APOE4 noncarriers (N=12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 45
Study: 38594680

Group type: EXPERIMENTAL
Intervention: GGOC-AD mobile app intervention module for 14 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: GGN-AD non-active module (control)
Number of subjects: 55
Study: 38594685

Group type: EXPERIMENTAL
Intervention: Automated health system-mediated strategy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Nonprofit foundation-mediated strategy with contact from a foundation-employed care navigator
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 220
Study: 38594710

Group type: EXPERIMENTAL
Intervention: Austrian OA Cuisine combined with GLA:D® programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: General information about a healthy lifestyle
Number of subjects: 60
Study: 38594727

Group type: EXPERIMENTAL
Intervention: Unsupervised robot-assisted therapy
Number of subjects: 13
Study: 38594725

Group type: EXPERIMENTAL
Intervention: CBT-I with bright light therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CBT-I with placebo light
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 150
Study: 38594733

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 38594737

Group type: EXPERIMENTAL
Intervention: Functional-Cognitive and Sensory Treatment (F-CaST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study: 38594740

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: In-person communication, multidisciplinary review, and medical record documentation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: COM-B domains (Opportunity-Social, Motivation-Reflective)
Number of subjects: 84
Study: 38594756

Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein, high-fiber (LFHP) diet
Number of subjects: 93

Group type: COMPARATOR
Intervention: High in mono-unsaturated fatty acids (HMUFA) diet
Number of subjects: 93
Study: 38594905

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (Sin+Chemo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 0
Study: 38595129

Group type: EXPERIMENTAL
Intervention: YYS 360
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: YYS 540
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: YYS 720
Number of subjects: 1022
Study: 38595232

Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) testing
Number of subjects: 424

Group type: COMPARATOR
Intervention: Serum creatinine levels
Number of subjects: 424

Group type: COMPARATOR
Intervention: Increased dd-cfDNA results (≥1%)
Number of subjects: 424
Study: 38595294

Group type: EXPERIMENTAL
Intervention: Surgical intervention plus weight-bearing walking training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight-bearing walking training alone
Number of subjects: 0
Study: 38595692

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 233
Study: 38595771

Group type: EXPERIMENTAL
Intervention: Mentored community gardening intervention
Number of subjects: 0
Study: 38596254

Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole for 5 days before hysterectomy
Number of subjects: 133

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 133
Study: 38596329

Group type: EXPERIMENTAL
Intervention: ESPRIMO intervention
Number of subjects: 53
Study: 38596515

Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention (patient-centered audit and feedback) with two audits (baseline and intermediate at 12 months) and educational resources.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention (patient-centered audit and feedback).
Number of subjects: 118

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 118
Study: 38596789

Group type: EXPERIMENTAL
Intervention: Burnout syndrome measured using the Maslach Burnout Inventory
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison with previous survey results from 2018
Number of subjects: 104
Study: 38596929

Group type: EXPERIMENTAL
Intervention: Handheld device
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cart-based model
Number of subjects: 110
Study: 38597172

Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (60 mg twice a day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once a day)
Number of subjects: 39
Study: 38597214

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) receiving 8 mg cyproheptadine and 5 mg prazosin ER daily
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) receiving 12 mg cyproheptadine and 10 mg prazosin ER daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo group (PG) receiving placebo of cyproheptadine and prazosin ER
Number of subjects: 154
Study: 38597249

Group type: EXPERIMENTAL
Intervention: Test-based attendance strategy (daily rapid antigen testing and staying at work if the test is negative)
Number of subjects: 16014

Group type: COMPARATOR
Intervention: Standard 10-day self-isolation
Number of subjects: 16014

Group type: EXPERIMENTAL
Intervention: Safety operating protocol with temperature and oxygen saturation checks and SARS-CoV-2 testing
Number of subjects: 16014
Study: 38597341

Group type: EXPERIMENTAL
Intervention: Non-surgical orthodontic treatment (including facemask, reverse Twin Block, orthodontic removable traction appliance, chin cup, tandem traction bow appliance, mandibular headgear)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Facemask treatment
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Surgical orthodontic treatment (surgical miniplates, facemask or Class III elastics)
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Facemask with RME
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Alternating rapid maxillary expansion and constriction
Number of subjects: 1169
Study: 38597388

Group type: EXPERIMENTAL
Intervention: Laparoscopic completion total gastrectomy (LCTG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open completion total gastrectomy (OCTG)
Number of subjects: 46
Study: 38597399

Group type: EXPERIMENTAL
Intervention: Ablation plus systemic therapy (AS)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Ablation alone (AB)
Number of subjects: 369
Study: 38597636

Group type: EXPERIMENTAL
Intervention: Capillary plasma samples
Number of subjects: 270

Group type: COMPARATOR
Intervention: Venous plasma samples
Number of subjects: 270
Study: 38597735

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 21
Study: 38597860

Group type: EXPERIMENTAL
Intervention: Posoleucel, a multivirus-specific T cell therapy
Number of subjects: 0
Study: 38597864

Group type: EXPERIMENTAL
Intervention: AT-001 (selective aldose reductase inhibitor) administered twice daily for 15 months
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 38597988

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg oral THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 38598132

Group type: EXPERIMENTAL
Intervention: Electronic handheld devices for PROMs
Number of subjects: 1342